雄激素受体与乳腺癌内分泌耐药的研究进展  

Research progress of androgen receptor and endocrine resistance in breast cancer

作　　者：王嘉铭 李宁宁 唐毅[1] 苏榕[1] WANG Jiaming;LI Ningning;TANG Yi;SU Rong(Department of Breast Sugery,the Third Affiliated Hospital of Guangzhou Medical University,Guangdong Guangzhou 510150,China)

机构地区：[1]广州医科大学附属第三医院乳腺外科,广东广州510150

出　　处：《现代肿瘤医学》2021年第3期524-527,共4页Journal of Modern Oncology

基　　金：广东省医学科学技术研究基金项目(编号:A2016441)。

摘　　要：乳腺癌是女性最常见的恶性肿瘤。其中雌激素受体(ER)阳性乳腺癌对内分泌治疗敏感,通过规范的内分泌治疗,患者复发及死亡风险显著降低。但是,内分泌耐药的出现成为临床治疗中最大的障碍。雄激素受体(AR)在ER阳性乳腺癌中广泛表达,与ER之间存在串扰,影响乳腺癌发展、内分泌耐药及预后。本文就AR在ER阳性乳腺癌中的作用机制、预后及内分泌治疗影响,尤其是内分泌耐药的相关研究进展进行综述。Breast cancer is the most common malignancies in females.Estrogen receptor(ER)positive breast cancer is sensitive to endocrine therapy,and the risk of recurrence and death is significantly reduced by standardized endocrine therapy.However,endocrine resistance has become the biggest obstacle in clinical treatment.Androgen receptor(AR)is widely expressed in ER-positive breast cancer,and there is the crosstalk between AR and ER,which affects cancer development,endocrine resistance and prognosis.This article reviews the role of AR in mechanism,prognosis and endocrine therapy,especially endocrine resistance in ER-positive breast cancer.

关 键 词：雄激素受体 乳腺癌 内分泌耐药 预后 

分 类 号：R737.9[医药卫生—肿瘤]